Worldwide orphan drug sales forecast to total $178bn in 2020
EvaluatePharma has just released their Orphan Drug Report 2015. This free report contains tons of great information on the current state of the market. A few highlights below: - Median cost per patient differential is 13.8 times higher for orphan drugs compared to non-orphan - Phase III orphan drug development costs half that of non-orphan but Phase III drug development - Worldwide orphan drug sales forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the ove
